Pregnancy Outcomes among Pregnant Persons after COVID-19 Vaccination: Assessing Vaccine Safety in Retrospective Cohort Analysis of U.S. National COVID Cohort Collaborative (N3C)

• Published in: Vaccines (Basel) Vol. 12; no. 3; p. 289
• Main Authors: Faherty, Emily A G, Wilkins, Kenneth J, Jones, Sara, Challa, Anup, Qin, Qiuyuan, Chan, Lauren E, Olson-Chen, Courtney, Tarleton, Jessica L, Liebman, Michael N, Mariona, Federico, Hill, Elaine L, Patel, Rena C, The N C Consortium
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.03.2024; MDPI
• Subjects: Birth rate; Births; Collaboration; COVID-19; COVID-19 vaccination; COVID-19 vaccines; Data models; Electronic health records; Electronic medical records; Ethnicity; FDA approval; Gestational age; Health aspects; Heterogeneity; Infections; Medical research; Miscarriage; mRNA vaccines; Pandemics; Pregnancy; Pregnant women; Premature birth; preterm birth; Public health; Review boards; Safety; Severe acute respiratory syndrome coronavirus 2; Sociodemographics; Stillbirth; U.S; Vaccines; United States; United States > US; preterm birth; COVID-19 vaccination; safety; pregnancy; stillbirth; real-world data; U.S
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines12030289

COVID-19 vaccines have been shown to be effective in preventing severe illness, including among pregnant persons. The vaccines appear to be safe in pregnancy, supporting a continuously favorable overall risk/benefit profile, though supportive data for the U.S. over different periods of variant predominance are lacking. We sought to analyze the association of adverse pregnancy outcomes with COVID-19 vaccinations in the pre-Delta, Delta, and Omicron SARS-CoV-2 variants' dominant periods (constituting 50% or more of each pregnancy) for pregnant persons in a large, nationally sampled electronic health record repository in the U.S. Our overall analysis included 311,057 pregnant persons from December 2020 to October 2023 at a time when there were approximately 3.6 million births per year. We compared rates of preterm births and stillbirths among pregnant persons who were vaccinated before or during pregnancy to persons vaccinated after pregnancy or those who were not vaccinated. We performed a multivariable Poisson regression with generalized estimated equations to address data site heterogeneity for preterm births and unadjusted exact models for stillbirths, stratified by the dominant variant period. We found lower rates of preterm birth in the majority of modeled periods (adjusted incidence rate ratio [aIRR] range: 0.42 to 0.85; -value range: <0.001 to 0.06) and lower rates of stillbirth (IRR range: 0.53 to 1.82; -value range: <0.001 to 0.976) in most periods among those who were vaccinated before or during pregnancy compared to those who were vaccinated after pregnancy or not vaccinated. We largely found no adverse associations between COVID-19 vaccination and preterm birth or stillbirth; these findings reinforce the safety of COVID-19 vaccination during pregnancy and bolster confidence for pregnant persons, providers, and policymakers in the importance of COVID-19 vaccination for this group despite the end of the public health emergency.